All study participants met criteria to remain off enzyme replacement therapy through 104 weeks after treatment.
NeoCart was originally developed by the company Histogenics.
The director of the Liver Tumor Program at Texas Children’s Hospital discussed a phase 1 study of CAR NK T-cells in neuroblastoma.
A final analysis of the pivotal HOPE-B study was presented at ASGCT 2022.
The cell therapy was tolerated although there was a SUSAR of GGT elevations.